Evidence map›Paper›PMID 42919963›Full record

ArticleNature medicine2026

Bispecific dual T cell agonist invikafusp alfa in solid tumors: the phase 1/2 START-001 trial.

Ryan J Sullivan, Nicholas P Tschernia, Claire F Friedman, Mercedes Herrera, Guru P Sonpavde, Kai He, Antoine Italiano, Aurélien Marabelle, Matthieu Roulleaux-Dugage, François-Xavier Danlos and 20 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Ryan J Sullivan *Mass General Brigham Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0001-5344-6645
Nicholas P Tschernia *Center for Cancer Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-2389-9974
Claire F Friedman *Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Mercedes HerreraPrincess Margaret Cancer Centre, Toronto, Ontario, Canada.ORCID http://orcid.org/0000-0002-8553-3919
Guru P SonpavdeAdventHealth Cancer Institute, Orlando, FL, USA.ORCID http://orcid.org/0000-0002-1010-9611
Kai HeThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.ORCID http://orcid.org/0000-0002-4378-9297
Antoine ItalianoInstitut Bergonié, Bordeaux, France.ORCID http://orcid.org/0000-0002-8540-5351
Aurélien MarabelleUniversity of Paris Saclay, Gustave Roussy Cancer Center, Villejuif, France.ORCID http://orcid.org/0000-0002-5816-3019
Matthieu Roulleaux-DugageUniversity of Paris Saclay, Gustave Roussy Cancer Center, Villejuif, France.ORCID http://orcid.org/0000-0003-3192-2342
François-Xavier DanlosUniversity of Paris Saclay, Gustave Roussy Cancer Center, Villejuif, France.
Elena Garralda CabanasMedical Oncology Department, Vall d'Hebron Hospital Campus and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.ORCID http://orcid.org/0000-0002-4412-7842
Alberto Hernando-CalvoMedical Oncology Department, Vall d'Hebron Hospital Campus and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Manuel PedregalSTART-FJD, Madrid, Spain.ORCID http://orcid.org/0009-0006-9760-9470
Aparna ParikhMass General Brigham Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-5245-7841
Gopakumar IyerMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-5093-6099
Ahmed ZakariAdventHealth Cancer Institute, Orlando, FL, USA.
E John WherryDepartment of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0003-0477-1956
Jeffrey SchlomCenter for Cancer Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0001-7932-4072
Renee N DonahueCenter for Cancer Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-6828-3073
Shannon McCueMarengo Therapeutics Inc., Cambridge, MA, USA.ORCID http://orcid.org/0009-0004-0950-5352
Sharon CrossMarengo Therapeutics Inc., Cambridge, MA, USA.
Karunya SrinivasanMarengo Therapeutics Inc., Cambridge, MA, USA.
Lisa BenincosaMarengo Therapeutics Inc., Cambridge, MA, USA.
Madan KatragaddaMarengo Therapeutics Inc., Cambridge, MA, USA.
Zhenming ShunMarengo Therapeutics Inc., Cambridge, MA, USA.
Kevin ChinMarengo Therapeutics Inc., Cambridge, MA, USA.
Zhen SuMarengo Therapeutics Inc., Cambridge, MA, USA.
Ke LiuMarengo Therapeutics Inc., Cambridge, MA, USA. kliu@marengotx.com.ORCID http://orcid.org/0009-0000-8391-3566
Lillian L SiuPrincess Margaret Cancer Centre, Toronto, Ontario, Canada. lillian.siu@uhn.ca.ORCID http://orcid.org/0000-0002-3500-0540
James L GulleyCenter for Cancer Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. gulleyj@mail.nih.gov.ORCID http://orcid.org/0000-0002-6569-2912

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Invikafusp alfa (invika), a first-in-class, bispecific, dual T cell agonistic antibody selectively targeting Vβ6/Vβ10 T cell subsets, is being evaluated in START-001, a multicenter phase 1/2 monotherapy trial in participants with mostly immune checkpoint blockade (ICB)-resistant, antigen-rich solid tumors. Primary outcomes were safety/tolerability and recommended phase 2 dose (RP2D) in phase 1 and anti-tumor activity in phase 2. As of 12 March 2025, phase 1 completed dose escalation (n = 34) through dose levels of 0.01, 0.02, 0.04, 0.08, 0.12 and 0.16 mg kg

Identifiers

PMID42919963

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.